Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abeona Therapeutics (ABEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 624,513
  • Shares Outstanding, K 46,780
  • Annual Sales, $ 890 K
  • Annual Income, $ -21,870 K
  • 36-Month Beta 1.23
  • Price/Sales 603.72
  • Price/Cash Flow N/A
  • Price/Book 5.99

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.50 +25.71%
on 02/15/18
18.90 -30.16%
on 02/08/18
-2.20 (-14.29%)
since 01/23/18
3-Month
10.50 +25.71%
on 02/15/18
18.90 -30.16%
on 02/08/18
-2.95 (-18.27%)
since 11/22/17
52-Week
4.55 +190.11%
on 06/16/17
22.75 -41.98%
on 10/11/17
+8.20 (+164.00%)
since 02/23/17

Most Recent Stories

More News
New Research Coverage Highlights Western Alliance, Matson, Vail Resorts, Abeona Therapeutics, Under Armour, and AGNC Investment -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Western Alliance Bancorporation...

WAL : 58.90 (+0.24%)
UAA : 16.76 (+0.84%)
ABEO : 13.20 (-1.12%)
AGNC : 18.84 (+1.29%)
MTN : 209.51 (-1.03%)
MATX : 29.50 (-0.54%)
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today...

ABEO : 13.20 (-1.12%)
Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial

- First-in-man AAV9-based gene therapy delivered by single intravenous injection targeting central nervous system and peripheral manifestations of MPS IIIB.

ABEO : 13.20 (-1.12%)
Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial

-- ABO-101 is well tolerated and demonstrates early biopotency signals with significant disease-specific heparan sulfate (HS) reductions in cerebral spinal fluid, urine, and plasma and greater than 300-fold...

ABEO : 13.20 (-1.12%)
Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium

NEW YORK and CLEVELAND, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies...

ABEO : 13.20 (-1.12%)
Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today...

ABEO : 13.20 (-1.12%)
Biotech Stocks' Research Reports Released on 22nd Century, Abeona Therapeutics, Acasti Pharma, and Aeterna Zentaris

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on XXII, ABEO, ACST, and AEZS which can be accessed for free by signing up to www.wallstequities.com/registration....

AEZS : 1.87 (-1.07%)
ABEO : 13.20 (-1.12%)
XXII : 2.72 (-0.37%)
ACST : 0.97 (unch)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of...

ABEO : 13.20 (-1.12%)
Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB

NEW YORK and CLEVELAND, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies...

ABEO : 13.20 (-1.12%)
Biotech Stocks' Research Reports Released on PhaseRx, Abeona Therapeutics, Imprimis Pharma, and Jaguar Health

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on PZRX, ABEO, IMMY, and JAGX which is a click away at www.wallstequities.com/registration....

IMMY : 1.75 (+2.34%)
PZRX : 0.28 (-9.68%)
ABEO : 13.20 (-1.12%)
JAGX : 0.14 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

See More

Key Turning Points

2nd Resistance Point 14.74
1st Resistance Point 14.04
Last Price 13.20
1st Support Level 12.26
2nd Support Level 11.18

See More

52-Week High 22.75
Fibonacci 61.8% 15.80
Fibonacci 50% 13.65
Last Price 13.20
Fibonacci 38.2% 11.50
52-Week Low 4.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.